News & Updates
Filter by Specialty:

EGFR-related skin AE rates drop with COCOON regimen
14 May 2025
byAudrey Abella
Interim data from the phase II COCOON trial demonstrate the potential of the COCOON dermatologic management (DM) regimen to significantly reduce the incidence and severity of dermatologic adverse events (dAEs) tied to amivantamab plus lazertinib treatment in patients with EGFR-mutant (EGFRm) non-small cell lung cancer (NSCLC).